person · Reporting owner

HENDERSON MICHAEL THOMAS

Disclosed activity across 4 companies

Tapewire entity: 1951
SEC CIK: 0001779990

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
BridgeBio Pharma, Inc.BBIO · Entity 3360	Chief Business Officer	December 15, 2020	December 17, 2020
Spyre Therapeutics, Inc.SYRE · Entity 2649	Director	June 22, 2026	June 24, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

BridgeBio Pharma, Inc.

Report date December 15, 2020 · Filed December 17, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.07 · Expires 2030-04-01	Direct	4,456	Reported balance After 2020-12-15 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2020-12-15 · Grant · Acquired 4,456 · Balance 4,456 F1: The option was acquired in connection with an equity exchange program involving the issuance of equity awards under the Issuer's 2019 Stock Option and Incentive Plan in exchange for existing equity held by the Reporting Person in a privately-held subsidiary of the Issuer. The number of option shares and per share exercise price of the new option was determined based on the number of shares and per share exercise price of the subsidiary option at a certain exchange ratio. F2: 1,671 shares subject to the stock option were vested as of the date of acquisition, 93 shares shall vest on January 1, 2021, and 2,692 shares shall vest in monthly installments over the next 29 months thereafter, in each case so long as the Reporting Person continues to have a service relationship with the Issuer or a Subsidiary on each such date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.07 · Expires 2030-07-20	Direct	3,137	Reported balance After 2020-12-15 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2020-12-15 · Grant · Acquired 3,137 · Balance 3,137 F1: The option was acquired in connection with an equity exchange program involving the issuance of equity awards under the Issuer's 2019 Stock Option and Incentive Plan in exchange for existing equity held by the Reporting Person in a privately-held subsidiary of the Issuer. The number of option shares and per share exercise price of the new option was determined based on the number of shares and per share exercise price of the subsidiary option at a certain exchange ratio. F3: 1,177 shares subject to the stock option were vested as of the date of acquisition, 65 shares shall vest on January 1, 2021, and 1,895 shares shall vest in monthly installments over the next 29 months thereafter, in each case so long as the Reporting Person continues to have a service relationship with the Issuer or a Subsidiary on each such date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $42.80 · Expires 2030-09-29	Direct	2,199	Reported balance After 2020-12-15 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-12-15 · Grant · Acquired 2,199 · Balance 2,199 F1: The option was acquired in connection with an equity exchange program involving the issuance of equity awards under the Issuer's 2019 Stock Option and Incentive Plan in exchange for existing equity held by the Reporting Person in a privately-held subsidiary of the Issuer. The number of option shares and per share exercise price of the new option was determined based on the number of shares and per share exercise price of the subsidiary option at a certain exchange ratio. F4: 825 shares subject to the stock option were vested as of the date of acquisition, 46 shares shall vest on January 1, 2021, and 1,328 shares shall vest in monthly installments over the next 29 months thereafter, in each case so long as the Reporting Person continues to have a service relationship with the Issuer or a Subsidiary on each such date.

Filing footnotes · ownership attribution and instrument terms

F1: The option was acquired in connection with an equity exchange program involving the issuance of equity awards under the Issuer's 2019 Stock Option and Incentive Plan in exchange for existing equity held by the Reporting Person in a privately-held subsidiary of the Issuer. The number of option shares and per share exercise price of the new option was determined based on the number of shares and per share exercise price of the subsidiary option at a certain exchange ratio.

F2: 1,671 shares subject to the stock option were vested as of the date of acquisition, 93 shares shall vest on January 1, 2021, and 2,692 shares shall vest in monthly installments over the next 29 months thereafter, in each case so long as the Reporting Person continues to have a service relationship with the Issuer or a Subsidiary on each such date.

F3: 1,177 shares subject to the stock option were vested as of the date of acquisition, 65 shares shall vest on January 1, 2021, and 1,895 shares shall vest in monthly installments over the next 29 months thereafter, in each case so long as the Reporting Person continues to have a service relationship with the Issuer or a Subsidiary on each such date.

F4: 825 shares subject to the stock option were vested as of the date of acquisition, 46 shares shall vest on January 1, 2021, and 1,328 shares shall vest in monthly installments over the next 29 months thereafter, in each case so long as the Reporting Person continues to have a service relationship with the Issuer or a Subsidiary on each such date.

Spyre Therapeutics, Inc.

Report date June 22, 2026 · Filed June 24, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	68,606	Reported balance After 2026-06-22 transaction · row 1 1 source row Row 1 · 2026-06-22 · Sale · Disposed 20,000 · Balance 68,606 F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 6, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 6, 2026.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ARYA Sciences Acquisition Corp IV

Report date July 31, 2024 · Filed August 01, 2024

Section 16 reporting ended · disclosed 2024-08-01. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class B ordinary sharesSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2024-07-31 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2024-07-31 · Disposition to issuer · Disposed 30,000 · Balance 0 F1: In connection with the Business Combination Agreement, dated February 13, 2024, by and among the Issuer, Adagio Medical Holdings, Inc. (f/k/a Aja HoldCo, Inc.) ("HoldCo"), Aja Merger Sub 1 ("Merger Sub 1"), Aja Merger Sub 2, Inc. ("Merger Sub 2") and Adagio Medical, Inc. ("Adagio") (the transactions contemplated thereby, the "Business Combination"), Merger Sub merged with and into the Issuer and Merger Sub 2 merged with and into Adagio, with each of the Issuer and Adagio becoming a wholly owned subsidiary of HoldCo, and the Reporting Person's ordinary shares of the Issuer were automatically converted into shares of common stock of HoldCo, par value $0.0001 per share, on a one-for-one basis.

Filing footnotes · ownership attribution and instrument terms

F1: In connection with the Business Combination Agreement, dated February 13, 2024, by and among the Issuer, Adagio Medical Holdings, Inc. (f/k/a Aja HoldCo, Inc.) ("HoldCo"), Aja Merger Sub 1 ("Merger Sub 1"), Aja Merger Sub 2, Inc. ("Merger Sub 2") and Adagio Medical, Inc. ("Adagio") (the transactions contemplated thereby, the "Business Combination"), Merger Sub merged with and into the Issuer and Merger Sub 2 merged with and into Adagio, with each of the Issuer and Adagio becoming a wholly owned subsidiary of HoldCo, and the Reporting Person's ordinary shares of the Issuer were automatically converted into shares of common stock of HoldCo, par value $0.0001 per share, on a one-for-one basis.

Apogee Therapeutics, Inc.

Report date September 03, 2026 · Filed September 03, 2026

Section 16 reporting ended · disclosed 2026-09-03. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2026-09-03 transaction · row 1 1 source row Row 1 · 2026-09-03 · Disposition to issuer · Disposed 920,941 · Balance 0 F1: The reported securities represent shares of the Issuer's common stock disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of June 18, 2026 (the "Merger Agreement"), among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.86 · Expires 2033-12-18	Direct	Reported balance After 2026-09-03 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-09-03 · Disposition to issuer · Disposed 387,012 · Balance 0 F3: Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option. F2: The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $49.07 · Expires 2034-12-09	Direct	Reported balance After 2026-09-03 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-09-03 · Disposition to issuer · Disposed 357,036 · Balance 0 F3: Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option. F2: The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $75.78 · Expires 2036-01-02	Direct	Reported balance After 2026-09-03 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-09-03 · Disposition to issuer · Disposed 253,016 · Balance 0 F3: Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option. F2: The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger.

Filing footnotes · ownership attribution and instrument terms

F1: The reported securities represent shares of the Issuer's common stock disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of June 18, 2026 (the "Merger Agreement"), among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc.

F2: The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger.

F3: Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
March 05, 2025 Filed Mar 8, 2025 01:01 UTC	Apogee Therapeutics, Inc. APGE · Entity 1939	SaleCommon Stock	7,326	$29.98	$219,633.48	Disclosure SEC source: 0001104659-25-021861 · tm258443-2_4seq1.xml · nonDerivative · entry 1 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,295,661 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 25, 2023. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.49 to $30.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
February 05, 2025 Filed Feb 8, 2025 01:01 UTC	Apogee Therapeutics, Inc. APGE · Entity 1939	SaleCommon Stock	15,000	$40.58	$608,700.00	Disclosure SEC source: 0001104659-25-010642 · tm255633-1_4seq1.xml · nonDerivative · entry 1 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,302,987 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 25, 2023. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.30 to $40.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
January 31, 2025 Filed Feb 1, 2025 01:00 UTC	Apogee Therapeutics, Inc. APGE · Entity 1939	Exercise / conversionStock Option (Right to Buy) · Derivative	8,500	$0.00 Strike: $22.86	$0.00	Disclosure SEC source: 0001104659-25-008235 · tm255141-1_4seq1.xml · derivative · entry 2 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 390,012 Underlying: Common Stock · 8,500 shares Expires 2033-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option represents the right to purchase 398,512 shares of the Issuer's common stock, one quarter of which vested on December 18, 2024, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer. Read SEC document
January 31, 2025 Filed Feb 1, 2025 01:00 UTC	Apogee Therapeutics, Inc. APGE · Entity 1939	Exercise / conversionCommon Stock	8,500	$22.86	$194,310.00	Disclosure SEC source: 0001104659-25-008235 · tm255141-1_4seq1.xml · nonDerivative · entry 1 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,317,987 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 10, 2025 Filed Jan 14, 2025 22:16 UTC	Spyre Therapeutics, Inc. SYRE · Entity 2649	OtherCommon Stock	105,379	$0.00	$0.00	Disclosure SEC source: 0001636282-25-000002 · wk-form4_1736892981.xml · nonDerivative · entry 1 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,379 F1 · kind: Represents the pro-rata distribution of shares of common stock for no consideration from a limited liability company in which the Reporting Person is a member. Read SEC document
January 08, 2025 Filed Jan 11, 2025 01:00 UTC	Apogee Therapeutics, Inc. APGE · Entity 1939	SaleCommon Stock	2,868	$49.38	$141,621.84	Disclosure SEC source: 0001104659-25-002688 · tm252859-1_4seq1.xml · nonDerivative · entry 2 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,309,487 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 25, 2023. F3 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $49.35 to $49.45, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range Read SEC document
January 08, 2025 Filed Jan 11, 2025 01:00 UTC	Apogee Therapeutics, Inc. APGE · Entity 1939	SaleCommon Stock	12,132	$48.72	$591,071.04	Disclosure SEC source: 0001104659-25-002688 · tm252859-1_4seq1.xml · nonDerivative · entry 1 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,312,355 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 25, 2023. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $48.20 to $49.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
December 09, 2024 Filed Dec 12, 2024 01:02 UTC	Apogee Therapeutics, Inc. APGE · Entity 1939	GrantStock Option (Right to Buy) · Derivative	357,036	$0.00 Strike: $49.07	$0.00	Disclosure SEC source: 0001104659-24-127707 · tm2430773-3_4seq1.xml · derivative · entry 1 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 357,036 Underlying: Common Stock · 357,036 shares Expires 2034-12-09 F1 · derivative.exercise_date: This option represents the right to purchase 357,036 shares of the Issuer's common stock, and will vest in forty-eight equal monthly installments over a four-year period from the date of grant, subject to the Reporting Person's continued service to the Issuer. Read SEC document
December 04, 2024 Filed Dec 7, 2024 01:01 UTC	Apogee Therapeutics, Inc. APGE · Entity 1939	SaleCommon Stock	1,672	$47.19	$78,901.68	Disclosure SEC source: 0001104659-24-126394 · tm2430233-2_4seq1.xml · nonDerivative · entry 2 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,324,487 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 25, 2023. F3 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $47.00 to $47.275, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
December 04, 2024 Filed Dec 7, 2024 01:01 UTC	Apogee Therapeutics, Inc. APGE · Entity 1939	SaleCommon Stock	13,328	$46.50	$619,752.00	Disclosure SEC source: 0001104659-24-126394 · tm2430233-2_4seq1.xml · nonDerivative · entry 1 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,326,159 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 25, 2023. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.00 to $46.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
November 06, 2024 Filed Nov 9, 2024 01:01 UTC	Apogee Therapeutics, Inc. APGE · Entity 1939	SaleCommon Stock	1,000	$59.94	$59,940.00	Disclosure SEC source: 0001104659-24-116024 · tm2427837-2_4seq1.xml · nonDerivative · entry 2 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,339,487 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 25, 2023. Read SEC document
November 06, 2024 Filed Nov 9, 2024 01:01 UTC	Apogee Therapeutics, Inc. APGE · Entity 1939	SaleCommon Stock	14,000	$59.17	$828,380.00	Disclosure SEC source: 0001104659-24-116024 · tm2427837-2_4seq1.xml · nonDerivative · entry 1 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,340,487 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 25, 2023. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $58.69 to $59.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
October 02, 2024 Filed Oct 5, 2024 00:01 UTC	Apogee Therapeutics, Inc. APGE · Entity 1939	SaleCommon Stock	9,712	$56.74	$551,058.88	Disclosure SEC source: 0001104659-24-106364 · tm2425574-2_4seq1.xml · nonDerivative · entry 2 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,354,487 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 25, 2023. F3 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $56.52 to $57.11, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
October 02, 2024 Filed Oct 5, 2024 00:01 UTC	Apogee Therapeutics, Inc. APGE · Entity 1939	SaleCommon Stock	30,288	$56.07	$1,698,248.16	Disclosure SEC source: 0001104659-24-106364 · tm2425574-2_4seq1.xml · nonDerivative · entry 1 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,364,199 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 25, 2023. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $55.51 to $56.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
September 04, 2024 Filed Sep 7, 2024 00:02 UTC	Apogee Therapeutics, Inc. APGE · Entity 1939	SaleCommon Stock	14,359	$48.23	$692,534.57	Disclosure SEC source: 0001104659-24-097866 · tm2423502-1_4seq1.xml · nonDerivative · entry 2 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,394,487 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 25, 2023. F3 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $47.95 to $48.54, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
September 04, 2024 Filed Sep 7, 2024 00:02 UTC	Apogee Therapeutics, Inc. APGE · Entity 1939	SaleCommon Stock	25,641	$47.28	$1,212,306.48	Disclosure SEC source: 0001104659-24-097866 · tm2423502-1_4seq1.xml · nonDerivative · entry 1 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,408,846 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 25, 2023. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.95 to $47.855, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
August 07, 2024 Filed Aug 10, 2024 00:05 UTC	Apogee Therapeutics, Inc. APGE · Entity 1939	SaleCommon Stock	100	$42.17	$4,217.00	Disclosure SEC source: 0001104659-24-087939 · tm2421174-1_4seq1.xml · nonDerivative · entry 3 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,434,487 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 25, 2023. Read SEC document
August 07, 2024 Filed Aug 10, 2024 00:05 UTC	Apogee Therapeutics, Inc. APGE · Entity 1939	SaleCommon Stock	7,667	$41.52	$318,333.84	Disclosure SEC source: 0001104659-24-087939 · tm2421174-1_4seq1.xml · nonDerivative · entry 2 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,434,587 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 25, 2023. F3 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.15 to $42.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range Read SEC document
August 07, 2024 Filed Aug 10, 2024 00:05 UTC	Apogee Therapeutics, Inc. APGE · Entity 1939	SaleCommon Stock	32,233	$40.40	$1,302,213.20	Disclosure SEC source: 0001104659-24-087939 · tm2421174-1_4seq1.xml · nonDerivative · entry 1 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,442,254 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 25, 2023. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.00 to $40.91, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
July 31, 2024 Filed Aug 1, 2024 01:49 UTC	ARYA Sciences Acquisition Corp IV ARYD · Entity 88618	Disposition to issuerClass B ordinary shares · Derivative	30,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001140361-24-035178 · form4.xml · derivative · entry 1 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A ordinary shares · 30,000 shares Expires not disclosed F1 · derivative.exercise_price: In connection with the Business Combination Agreement, dated February 13, 2024, by and among the Issuer, Adagio Medical Holdings, Inc. (f/k/a Aja HoldCo, Inc.) ("HoldCo"), Aja Merger Sub 1 ("Merger Sub 1"), Aja Merger Sub 2, Inc. ("Merger Sub 2") and Adagio Medical, Inc. ("Adagio") (the transactions contemplated thereby, the "Business Combination"), Merger Sub merged with and into the Issuer and Merger Sub 2 merged with and into Adagio, with each of the Issuer and Adagio becoming a wholly owned subsidiary of HoldCo, and the Reporting Person's ordinary shares of the Issuer were automatically converted into shares of common stock of HoldCo, par value $0.0001 per share, on a one-for-one basis. F1 · kind: In connection with the Business Combination Agreement, dated February 13, 2024, by and among the Issuer, Adagio Medical Holdings, Inc. (f/k/a Aja HoldCo, Inc.) ("HoldCo"), Aja Merger Sub 1 ("Merger Sub 1"), Aja Merger Sub 2, Inc. ("Merger Sub 2") and Adagio Medical, Inc. ("Adagio") (the transactions contemplated thereby, the "Business Combination"), Merger Sub merged with and into the Issuer and Merger Sub 2 merged with and into Adagio, with each of the Issuer and Adagio becoming a wholly owned subsidiary of HoldCo, and the Reporting Person's ordinary shares of the Issuer were automatically converted into shares of common stock of HoldCo, par value $0.0001 per share, on a one-for-one basis. F1 · price: In connection with the Business Combination Agreement, dated February 13, 2024, by and among the Issuer, Adagio Medical Holdings, Inc. (f/k/a Aja HoldCo, Inc.) ("HoldCo"), Aja Merger Sub 1 ("Merger Sub 1"), Aja Merger Sub 2, Inc. ("Merger Sub 2") and Adagio Medical, Inc. ("Adagio") (the transactions contemplated thereby, the "Business Combination"), Merger Sub merged with and into the Issuer and Merger Sub 2 merged with and into Adagio, with each of the Issuer and Adagio becoming a wholly owned subsidiary of HoldCo, and the Reporting Person's ordinary shares of the Issuer were automatically converted into shares of common stock of HoldCo, par value $0.0001 per share, on a one-for-one basis. F1 · derivative.exercise_date: In connection with the Business Combination Agreement, dated February 13, 2024, by and among the Issuer, Adagio Medical Holdings, Inc. (f/k/a Aja HoldCo, Inc.) ("HoldCo"), Aja Merger Sub 1 ("Merger Sub 1"), Aja Merger Sub 2, Inc. ("Merger Sub 2") and Adagio Medical, Inc. ("Adagio") (the transactions contemplated thereby, the "Business Combination"), Merger Sub merged with and into the Issuer and Merger Sub 2 merged with and into Adagio, with each of the Issuer and Adagio becoming a wholly owned subsidiary of HoldCo, and the Reporting Person's ordinary shares of the Issuer were automatically converted into shares of common stock of HoldCo, par value $0.0001 per share, on a one-for-one basis. F1 · derivative.expiration_date: In connection with the Business Combination Agreement, dated February 13, 2024, by and among the Issuer, Adagio Medical Holdings, Inc. (f/k/a Aja HoldCo, Inc.) ("HoldCo"), Aja Merger Sub 1 ("Merger Sub 1"), Aja Merger Sub 2, Inc. ("Merger Sub 2") and Adagio Medical, Inc. ("Adagio") (the transactions contemplated thereby, the "Business Combination"), Merger Sub merged with and into the Issuer and Merger Sub 2 merged with and into Adagio, with each of the Issuer and Adagio becoming a wholly owned subsidiary of HoldCo, and the Reporting Person's ordinary shares of the Issuer were automatically converted into shares of common stock of HoldCo, par value $0.0001 per share, on a one-for-one basis. Read SEC document
July 05, 2024 Filed Jul 6, 2024 00:01 UTC	Apogee Therapeutics, Inc. APGE · Entity 1939	SaleCommon Stock	15,000	$37.26	$558,900.00	Disclosure SEC source: 0001104659-24-078135 · tm2418983-2_4seq1.xml · nonDerivative · entry 1 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,474,487 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 25, 2023. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.78 to $37.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
May 14, 2024 Filed May 16, 2024 20:10 UTC	Spyre Therapeutics, Inc. SYRE · Entity 2649	GrantStock Option (Right to Buy) · Derivative	11,323	$0.00 Strike: $39.29	$0.00	Disclosure SEC source: 0000950170-24-061080 · ownership.xml · derivative · entry 1 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,323 Underlying: Common Stock · 11,323 shares Expires 2034-05-14 F1 · derivative.exercise_date: This option represents a right to purchase 11,323 shares of the Issuer's common stock, which will vest and become exercisable in 12 equal monthly installments following May 14, 2024 until such time as the option is 100% vested, subject to the Reporting Person's continuous service with the Issuer at each vesting date. Read SEC document
December 18, 2023 Filed Dec 21, 2023 01:00 UTC	Apogee Therapeutics, Inc. APGE · Entity 1939	GrantStock Option (Right to Buy) · Derivative	398,512	$0.00 Strike: $22.86	$0.00	Disclosure SEC source: 0001104659-23-127819 · tm2333399-1_4seq1.xml · derivative · entry 1 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 398,512 Underlying: Common Stock · 398,512 shares Expires 2033-12-18 F1 · derivative.exercise_date: This option represents the right to purchase 398,512 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments over a four-year period from the date of grant, subject to the Reporting Person's continued service to the Issuer. Read SEC document
December 15, 2020 Filed Dec 17, 2020 21:05 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	GrantStock Option (Right to Buy) · Derivative	2,199	$0.00 Strike: $42.80	$0.00	Disclosure SEC source: 0000899243-20-034282 · doc4.xml · derivative · entry 3 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,199 Underlying: Common Stock · 2,199 shares Expires 2030-09-29 F1 · kind: The option was acquired in connection with an equity exchange program involving the issuance of equity awards under the Issuer's 2019 Stock Option and Incentive Plan in exchange for existing equity held by the Reporting Person in a privately-held subsidiary of the Issuer. The number of option shares and per share exercise price of the new option was determined based on the number of shares and per share exercise price of the subsidiary option at a certain exchange ratio. F4 · derivative.exercise_date: 825 shares subject to the stock option were vested as of the date of acquisition, 46 shares shall vest on January 1, 2021, and 1,328 shares shall vest in monthly installments over the next 29 months thereafter, in each case so long as the Reporting Person continues to have a service relationship with the Issuer or a Subsidiary on each such date. Read SEC document
December 15, 2020 Filed Dec 17, 2020 21:05 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	GrantStock Option (Right to Buy) · Derivative	3,137	$0.00 Strike: $3.07	$0.00	Disclosure SEC source: 0000899243-20-034282 · doc4.xml · derivative · entry 2 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,137 Underlying: Common Stock · 3,137 shares Expires 2030-07-20 F1 · kind: The option was acquired in connection with an equity exchange program involving the issuance of equity awards under the Issuer's 2019 Stock Option and Incentive Plan in exchange for existing equity held by the Reporting Person in a privately-held subsidiary of the Issuer. The number of option shares and per share exercise price of the new option was determined based on the number of shares and per share exercise price of the subsidiary option at a certain exchange ratio. F3 · derivative.exercise_date: 1,177 shares subject to the stock option were vested as of the date of acquisition, 65 shares shall vest on January 1, 2021, and 1,895 shares shall vest in monthly installments over the next 29 months thereafter, in each case so long as the Reporting Person continues to have a service relationship with the Issuer or a Subsidiary on each such date. Read SEC document
December 15, 2020 Filed Dec 17, 2020 21:05 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	GrantStock Option (Right to Buy) · Derivative	4,456	$0.00 Strike: $3.07	$0.00	Disclosure SEC source: 0000899243-20-034282 · doc4.xml · derivative · entry 1 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,456 Underlying: Common Stock · 4,456 shares Expires 2030-04-01 F1 · kind: The option was acquired in connection with an equity exchange program involving the issuance of equity awards under the Issuer's 2019 Stock Option and Incentive Plan in exchange for existing equity held by the Reporting Person in a privately-held subsidiary of the Issuer. The number of option shares and per share exercise price of the new option was determined based on the number of shares and per share exercise price of the subsidiary option at a certain exchange ratio. F2 · derivative.exercise_date: 1,671 shares subject to the stock option were vested as of the date of acquisition, 93 shares shall vest on January 1, 2021, and 2,692 shares shall vest in monthly installments over the next 29 months thereafter, in each case so long as the Reporting Person continues to have a service relationship with the Issuer or a Subsidiary on each such date. Read SEC document
December 01, 2020 Filed Dec 2, 2020 21:17 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	Exercise / conversionStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $1.05	$0.00	Disclosure SEC source: 0000899243-20-032507 · doc4.xml · derivative · entry 4 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,282 Underlying: Common Stock · 10,000 shares Expires 2029-09-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020. Read SEC document
December 01, 2020 Filed Dec 2, 2020 21:17 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	SaleCommon Stock	6,972	$51.69	$360,408.48	Disclosure SEC source: 0000899243-20-032507 · doc4.xml · nonDerivative · entry 3 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,211 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020. F3 · price: Represents the weighted average sale price of the shares sold from $51.41 to $52.36 per share. Read SEC document
December 01, 2020 Filed Dec 2, 2020 21:17 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	SaleCommon Stock	3,028	$51.12	$154,795.60	Disclosure SEC source: 0000899243-20-032507 · doc4.xml · nonDerivative · entry 2 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 281,183 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020. F2 · price: Represents the weighted average sale price of the shares sold from $50.41 to $51.40 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3. Read SEC document
December 01, 2020 Filed Dec 2, 2020 21:17 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	Exercise / conversionCommon Stock	10,000	$1.05	$10,500.00	Disclosure SEC source: 0000899243-20-032507 · doc4.xml · nonDerivative · entry 1 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 284,211 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020. Read SEC document
November 16, 2020 Filed Nov 19, 2020 00:43 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	Exercise / conversionRestricted Stock Units · Derivative	12,813	$0.00	$0.00	Disclosure SEC source: 0000899243-20-031557 · doc4.xml · derivative · entry 6 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,375 Underlying: Common Stock · 12,813 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: The RSUs vest over approximately four years with a vesting commencement date of May 16, 2020 and have no expiration date. 6.25% of the RSUs vested on August 16, 2020 and November 16, 2020 and an additional 6.25% will vest in quarterly installments on the 16th day of each February, May, August and November thereafter, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. F4 · derivative.expiration_date: The RSUs vest over approximately four years with a vesting commencement date of May 16, 2020 and have no expiration date. 6.25% of the RSUs vested on August 16, 2020 and November 16, 2020 and an additional 6.25% will vest in quarterly installments on the 16th day of each February, May, August and November thereafter, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. Read SEC document
November 16, 2020 Filed Nov 19, 2020 00:43 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	Exercise / conversionStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $1.05	$0.00	Disclosure SEC source: 0000899243-20-031557 · doc4.xml · derivative · entry 5 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,282 Underlying: Common Stock · 10,000 shares Expires 2029-09-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020. Read SEC document
November 16, 2020 Filed Nov 19, 2020 00:43 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	Tax withholdingCommon Stock	6,353	$44.33	$281,628.49	Disclosure SEC source: 0000899243-20-031557 · doc4.xml · nonDerivative · entry 4 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,211 F3 · shares: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 12,813 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document
November 16, 2020 Filed Nov 19, 2020 00:43 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	Exercise / conversionCommon Stock	12,813	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-20-031557 · doc4.xml · nonDerivative · entry 3 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,564 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document
November 16, 2020 Filed Nov 19, 2020 00:43 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	SaleCommon Stock	10,000	$45.00	$450,000.00	Disclosure SEC source: 0000899243-20-031557 · doc4.xml · nonDerivative · entry 2 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,751 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020. Read SEC document
November 16, 2020 Filed Nov 19, 2020 00:43 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	Exercise / conversionCommon Stock	10,000	$1.05	$10,500.00	Disclosure SEC source: 0000899243-20-031557 · doc4.xml · nonDerivative · entry 1 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 277,751 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020. Read SEC document
November 02, 2020 Filed Nov 3, 2020 21:05 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	Exercise / conversionStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $1.05	$0.00	Disclosure SEC source: 0000899243-20-030214 · doc4.xml · derivative · entry 4 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,282 Underlying: Common Stock · 10,000 shares Expires 2029-09-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020. Read SEC document
November 02, 2020 Filed Nov 3, 2020 21:05 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	SaleCommon Stock	500	$38.92	$19,457.80	Disclosure SEC source: 0000899243-20-030214 · doc4.xml · nonDerivative · entry 3 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,751 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020. F3 · price: Represents the weighted average sale price of the shares sold from $38.86 to $38.97 per share. Read SEC document
November 02, 2020 Filed Nov 3, 2020 21:05 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	SaleCommon Stock	9,500	$38.33	$364,099.85	Disclosure SEC source: 0000899243-20-030214 · doc4.xml · nonDerivative · entry 2 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,251 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020. F2 · price: Represents the weighted average sale price of the shares sold from $37.80 to $38.79 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3. Read SEC document
November 02, 2020 Filed Nov 3, 2020 21:05 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	Exercise / conversionCommon Stock	10,000	$1.05	$10,500.00	Disclosure SEC source: 0000899243-20-030214 · doc4.xml · nonDerivative · entry 1 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 277,751 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020. Read SEC document
October 01, 2020 Filed Oct 5, 2020 20:05 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	Exercise / conversionStock Option (Right to Buy) · Derivative	6,745	$0.00 Strike: $1.05	$0.00	Disclosure SEC source: 0000899243-20-027232 · doc4.xml · derivative · entry 7 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,282 Underlying: Common Stock · 6,745 shares Expires 2029-09-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020. Read SEC document
October 01, 2020 Filed Oct 5, 2020 20:05 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	Exercise / conversionStock Option (Right to Buy) · Derivative	1,019	$0.00 Strike: $0.28	$0.00	Disclosure SEC source: 0000899243-20-027232 · doc4.xml · derivative · entry 6 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,019 shares Expires 2028-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020. Read SEC document
October 01, 2020 Filed Oct 5, 2020 20:05 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	Exercise / conversionStock Option (Right to Buy) · Derivative	2,236	$0.00 Strike: $0.28	$0.00	Disclosure SEC source: 0000899243-20-027232 · doc4.xml · derivative · entry 5 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,236 shares Expires 2027-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020. Read SEC document
October 01, 2020 Filed Oct 5, 2020 20:05 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	SaleCommon Stock	5,505	$39.28	$216,248.51	Disclosure SEC source: 0000899243-20-027232 · doc4.xml · nonDerivative · entry 4 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,751 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020. F3 · price: Represents the weighted average sale price of the shares sold from $38.81 to $39.71 per share. Read SEC document
October 01, 2020 Filed Oct 5, 2020 20:05 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	SaleCommon Stock	4,495	$38.29	$172,093.32	Disclosure SEC source: 0000899243-20-027232 · doc4.xml · nonDerivative · entry 3 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 273,256 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020. F2 · price: Represents the weighted average sale price of the shares sold from $37.74 to $38.72 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3. Read SEC document
October 01, 2020 Filed Oct 5, 2020 20:05 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	Exercise / conversionCommon Stock	6,745	$1.05	$7,082.25	Disclosure SEC source: 0000899243-20-027232 · doc4.xml · nonDerivative · entry 2 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 277,751 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020. Read SEC document
October 01, 2020 Filed Oct 5, 2020 20:05 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	Exercise / conversionCommon Stock	3,255	$0.28	$911.40	Disclosure SEC source: 0000899243-20-027232 · doc4.xml · nonDerivative · entry 1 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 271,006 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020. Read SEC document
September 18, 2020 Filed Sep 22, 2020 23:05 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	Exercise / conversionStock Option (Right to Buy) · Derivative	5,099	$0.00 Strike: $0.28	$0.00	Disclosure SEC source: 0000899243-20-025961 · doc4.xml · derivative · entry 5 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,236 Underlying: Common Stock · 5,099 shares Expires 2027-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020. Read SEC document
September 18, 2020 Filed Sep 22, 2020 23:05 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	Exercise / conversionStock Option (Right to Buy) · Derivative	4,901	$0.00 Strike: $0.16	$0.00	Disclosure SEC source: 0000899243-20-025961 · doc4.xml · derivative · entry 4 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,586 Underlying: Common Stock · 4,901 shares Expires 2028-08-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020. Read SEC document
September 18, 2020 Filed Sep 22, 2020 23:05 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	SaleCommon Stock	10,000	$40.00	$400,000.00	Disclosure SEC source: 0000899243-20-025961 · doc4.xml · nonDerivative · entry 3 HENDERSON MICHAEL THOMAS · CIK 0001779990 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,751 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.